Nava Sarver

2.8k total citations · 1 hit paper
39 papers, 2.3k citations indexed

About

Nava Sarver is a scholar working on Molecular Biology, Virology and Genetics. According to data from OpenAlex, Nava Sarver has authored 39 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 13 papers in Virology and 13 papers in Genetics. Recurrent topics in Nava Sarver's work include Virus-based gene therapy research (13 papers), HIV Research and Treatment (13 papers) and RNA and protein synthesis mechanisms (10 papers). Nava Sarver is often cited by papers focused on Virus-based gene therapy research (13 papers), HIV Research and Treatment (13 papers) and RNA and protein synthesis mechanisms (10 papers). Nava Sarver collaborates with scholars based in United States, Bulgaria and Israel. Nava Sarver's co-authors include Peter M. Howley, John J. Rossi, J C Byrne, Edouard M. Cantin, Paula Ladne, John A. Zaia, Victor Stollar, Ming-Fan Law, Sandra H. Bridges and Joseph Schlessinger and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Nava Sarver

38 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ribozymes as Potential Anti-HIV-1 Therapeutic Agents

1990 536 citations Nava Sarver, Edouard M. Cantin et al. profile →

Peers

Countries citing papers authored by Nava Sarver

Since Specialization

Citations

This map shows the geographic impact of Nava Sarver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nava Sarver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nava Sarver more than expected).

Fields of papers citing papers by Nava Sarver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nava Sarver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nava Sarver. The network helps show where Nava Sarver may publish in the future.

Co-authorship network of co-authors of Nava Sarver

This figure shows the co-authorship network connecting the top 25 collaborators of Nava Sarver. A scholar is included among the top collaborators of Nava Sarver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nava Sarver. Nava Sarver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mini-Review : New Viral Vectors for HIV Vaccine Delivery 1998 ·AIDS Research and Human Retroviruses ·J. Scott Cairns, Nava Sarver	6
2	HIV accessory proteins as therapeutic targets 1997 ·Nature Medicine ·R.H. Miller, Nava Sarver	54
3	Gene Therapy for HIV-1 Infection 1996 ·Advances in experimental medicine and biology ·Donald B. Kohn, Nava Sarver	20
4	Conference Summary: Novel HIV Therapies—From Discovery to Clinical Proof of Concept 1996 ·AIDS Research and Human Retroviruses ·R.H. Miller, (unknown), Roberta Black, Sandra H. Bridges, Nava Sarver	4
5	Gene therapy and immune restoration for HIV disease 1995 ·The Lancet ·Nava Sarver, Sandra H. Bridges	55
6	Cellular Distribution of HIV Type 1 Nef Protein: Identification of Domains in Nef Required for Association with Membrane and Detergent-Insoluble Cellular Matrix 1994 ·AIDS Research and Human Retroviruses ·(unknown), Raanan Margalit, (unknown), Heidi E. Drummer, Boaz Amit, Nava Sarver, Marian Gorecki, Amos Panet	50
7	Gene Therapy: A Bold Direction for HIV-1 Treatment* 1993 ·AIDS Research and Human Retroviruses ·Nava Sarver, John J. Rossi	25
8	Ribozymes: Use as Anti-HIV Therapeutic Molecules 1993 ·PubMed ·Boro Dropulić, (unknown), John J. Rossi, Nava Sarver	14
9	Frontiers in HIV-1 Therapy: Fourth Conference of the NIAID National Cooperative Drug Discovery Groups-HIV 1992 ·AIDS Research and Human Retroviruses ·Nava Sarver, Roberta Black, Sandra H. Bridges, Linda A. Chrisey	12
10	Molecular characterization of HIV1 nef protein 1992 ·Research in Virology ·(unknown), Nava Sarver, Marian Gorecki, Amos Panet	0
11	Catalytic Antisense RNA (Ribozymes): Their Potential and Use as ANTI-HIV-1 Therapeutic Agents 1992 ·Advances in experimental medicine and biology ·John J. Rossi, Nava Sarver	22
12	Ribozymes: A New Frontier in Anti-HIV Strategy 1991 ·PubMed ·Nava Sarver	7
13	MEETING REPORT Ribozymes: Progress and Prospects of Catalytic RNA as Therapeutic Agents 1991 ·PubMed ·Linda A. Chrisey, John J. Rossi, Nava Sarver	10
14	The potential use of catalytic RNAs in therapy of HIV infection and other diseases 1991 ·Pharmacology & Therapeutics ·John J. Rossi, Edouard M. Cantin, Nava Sarver, (unknown)	30
15	Ribozymes as Therapies for AIDS^a 1990 ·Annals of the New York Academy of Sciences ·John J. Rossi, Edouard M. Cantin, John Zaia, Paula Ladne, Jian Chen, (unknown), Nava Sarver, (unknown)	11
16	Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications 1989 ·JNCI Journal of the National Cancer Institute ·Mace L. Rothenberg, Gregory A. Johnson, Catherine Laughlin, I. Green, James C. Cradock, Nava Sarver, Jack S. Cohen	47
17	Utilization of an Epstein-Barr virus replicon as a eukaryotic expression vector 1988 ·Gene ·Janet M. Young, Christopher Cheadle, James S. Foulke, William N. Drohan, Nava Sarver	42
18	Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumorigenesis to Swiss 3T3 cells. 1988 ·The EMBO Journal ·Michael Jaye, Raymond M. Lyall, (unknown), Joseph Schlessinger, Nava Sarver	132
19	Stable Expression of Recombinant Factor VIII Molecules Using a Bovine Papillomavirus Vector 1987 ·DNA ·Nava Sarver, George A. Ricca, John S. Link, Margret Nathan, Jack Newman, William N. Drohan	22
20	Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interaction 1987 ·Nucleic Acids Research ·David R. Hurwitz, (unknown), William N. Drohan, Nava Sarver	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact